Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12850750 | 0.88 | GPR84 (0.79) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL29202652 | 0.88 | GPR84 (0.77) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL1094688 | 0.85 | GPR84 (0.74) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL256689 | 0.85 | GPR84 (0.74) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL1093225 | 0.84 | GPR84 (0.72) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL30980816 | 0.84 | GPR84 (0.72) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL3093301 | 0.84 | GPR84 (0.71) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL3083899 | 0.84 | GPR84 (0.71) | GPR84HTR2AAHRCA2KEAP1 | |
| SCHEMBL29007213 | 0.83 | GPR84 (0.70) | GPR84HTR2AAHRCA2ALDH1A1 | |
| SCHEMBL5212531 | 0.83 | HTR2A (0.73) | GPR84HTR2AAHRCA2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634438-B | Preparation method of bisindolyl methane and derivative thereof | 兰州大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-114634438-A | Preparation method of diindolylmethane and derivatives thereof | 兰州大学 | 2022-06-17 | — | — | CN | disclosed |
| US-7074938-B2 | Method for the synthesis of soritin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040147585-A1 | Method for the synthesis of Soritin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147585-A1 | Method for the synthesis of Soritin compounds | SUCLA2, SUCLG2, SUCNR1 | GPR84 4401/4885HTR2A 879/4885AHR 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.